Organic Active Ingredients TRIZ Cases

6-aza tetracyclic oxazepines target KRasG12D to restore Ras signaling termination and suppress cancer cell proliferation and metastasis.

Embedding corallopyronin A in a water-soluble polymer creates a stable amorphous dispersion for oral dosing with improved solubility and bioavailability.

Targeting DGAT1 relieves opioid-induced constipation by increasing fecal output while avoiding the broad side effects of standard laxatives.

Multi-ethnic genomic screening links ALS risk genotypes to compounds that prolong motor neuron neurite length and speed candidate selection.

Formula 1 compounds selectively block prostaglandin transporter activity to raise PGE2 and prostacyclin with fewer off-target effects.

Controlled-release D-mannose granules use HPMC, oils, and waxes to sustain urinary levels, inhibit adhesion, and reduce frequent dosing.

An acidic selenate or seleno-amino acid formulation keeps parenteral selenium stable in storage and avoids manual bag mixing errors.

Combining ATR inhibitor AZD6738 with paclitaxel improves chemotherapy response in melanoma after prior PD-1 or PD-L1 immunotherapy.

Specific thienopyrimidine salts and crystal forms improve stability, flowability, and oral bioavailability for GnRH receptor antagonists.

Combining plerixafor stem cell mobilization with low-dose tacrolimus supports graft acceptance while reducing chronic immunosuppression side effects.

A five-step cyclization, chiral reduction, and hydrolysis route cuts synthesis steps while delivering high-purity pyrrolopyridine derivatives for mass production.

Pulsed GnRH delivery restores natural secretion rhythms to reverse olfactory and cognitive impairments linked to GnRH deficiency.

A two-phase PI3Kδ inhibitor regimen uses induction then lower-dose maintenance to preserve efficacy while reducing toxicity in B-cell disorders.

Structural tuning of pyrazolo[1,5-a]pyrimidine-7-amine derivatives improves CDK9 selectivity, potency, and in vivo pharmacokinetics.

A hydrophilic self-immolative linker improves ADC stability, solubility, pharmacokinetics, and anti-tumor activity in low-receptor tumors.

Genetically modified Pantoea agglomerans produces high-purity low-mass lipopolysaccharide directly, cutting gel filtration cost and easing scale-up.

Rapid IV cangrelor provides reversible platelet inhibition after pediatric shunt surgery or stent implantation to cover the early thrombosis risk window.

Targets immune cell surface antigens to deliver therapeutic agents in vivo, avoiding ex vivo cell modification and autologous collection.

Formula I aza-quinoline compounds inhibit EZH2 to reactivate gene expression, suppress tumor growth, and support broader cancer treatment.

Pyridazinone compounds block TRPC4/5 channels to address the lack of effective inhibitors for kidney and liver disease treatment.

Heterobifunctional compounds degrade TTBK1 instead of competing with ATP, lowering tau phosphorylation and total tau in tauopathies.

Controlled crystallization forms 3',3'-cGAMP hydrate crystals with lower hygroscopicity, better shelf life, and easier scale-up than lyophilized powder.

Gentle centrifugation, microfiltration, and freeze-drying preserve bovine milk exosome membranes and miRNA in a stable powder.

Defined 36-50 saccharide heparan sulphate fragments improve BMP2 binding to enhance osteoblast differentiation, bone repair, and wound healing.

Targeting Cryptosporidium PI4K, these compounds improve treatment effectiveness where current therapies fall short, especially in vulnerable patients.

Targeted FXII RNAi delivery to liver cells suppresses Factor XII expression to prevent thrombosis and angioedema with lower hemorrhage risk.

Small molecules targeting conserved hemagglutinin fusion regions block viral entry and help address influenza drug resistance.

A stable thiol-linked conjugate avoids amide hydrolysis and reverse Michael addition, improving tumor exposure while reducing toxicity.

Chemical modification of quinolone analogs enables oral tumor treatment with improved bioavailability, metabolic stability, and lower toxicity.

Novel pyridinyl-triazolyl benzothiazinone derivatives strengthen ASK-1 inhibition for treating metabolic and other ASK-1 mediated diseases.

BDDE crosslinking keeps triamcinolone evenly dispersed in hyaluronic acid gel, extending intra-articular release without surfactant instability.

Oral sodium benzoate inhibits D-amino acid oxidase to enhance NMDA receptor function and treat refractory anti-NMDAR encephalitis.

Direct prostate injection of a sustained-release cytostatic or cytotoxic formulation treats BPH with faster local effect and less urethral trauma.

Electrowetting and a porous diffusion layer enable on-demand transdermal release, variable dosing, and multi-drug delivery from one patch.

C-17 substitution in 19-alkoxy neuroactive steroids improves GABA A receptor activity, anesthetic efficacy, solubility, and contamination control.

Heteroaryl methacrylic acids improve metabolic stability and systemic exposure while reducing cytokine release through NRF2 activation.

A glucuronic acid-1-phosphate and tetracalcium phosphate graft balances rapid setting, bond strength, biocompatibility, and controlled resorption.

An EGFR-targeted ADC uses antibody-guided delivery and a cleavable linker to treat resistant solid tumors with lower toxicity.

Small molecules block UBE3A-mediated ubiquitination, offering a drug lead for autism-related overactivity and HPV-driven cancers.

Bridged nucleic acids placed around mismatch sites improve intracellular DNA editing by resisting mismatch repair and raising editing yield.

Temporary high-dose dexamethasone or betamethasone depletes lymphocytes while sparing other cells, reducing toxicity and relapse risk.

Targeting MAT2A with sulfone derivatives disrupts methionine salvage and suppresses growth in MTAP-deleted cancers.

Cyclodextrin-based leucovorin calcium formulations prevent crystallization in refrigerated storage, enabling a clear ready-to-use injection.

Controlled-OTR translucent polypropylene bags keep dilute phenylephrine stable without opaque overwraps, enabling impurity inspection and longer shelf life.

Pridopidine targets Sigma-1 and dopamine D2 receptors to reduce dystonic muscle contractions across multiple dystonia types.

By crossing the blood-brain barrier and raising PGC-1α in the brain, this composition protects dopaminergic neurons beyond symptom relief.

Novel Formula I small molecules inhibit RSV and MPV replication, offering a safer, more accessible alternative to vaccines and monoclonal prophylaxis.

Blocking CD47 signaling with 1,2,4-oxadiazole compounds boosts macrophage phagocytosis and helps restore antitumor immune surveillance.

A one-pot tedizolid intermediate route uses Vilsmeier chemistry to avoid cyanide, azide, palladium, and ultra-low-temperature processing.

Anti-V5 and fluorescent antibody readout enables hybrid cyclic libraries to screen the human proteome without tag interference.

New crystalline, salt, and co-crystal forms of a pyrimido-diazepine PLK1 inhibitor improve stability, handling, and bioavailability while limiting toxicity.

When direct RAS inhibitors fail, mutant peptide compositions and TCRs enable HLA-specific immune killing of G12-mutant cancer cells.

Timed kit compartments, non-verbal instructions, and app tracking improve MRSA decolonization compliance while limiting resistance.

Combining asparagine restriction with ASNS synthetic lethal partner inhibition blocks metabolic rewiring and suppresses melanoma and pancreatic tumors.

Topical Wnt inhibitors reduce hyperactive WNT signaling in TMEM79-linked atopic dermatitis to improve skin barrier integrity.

Cyclo-Z targets NF-κB-driven inflammation and immune dysfunction to restore β-cell activity and insulin sensitivity in diabetes.

Lumateperone mono-tosylate capsules improve CNS treatment by combining rapid onset with selective serotonin and dopamine pathway targeting.

Timed vaccination before or between cladribine cycles helps preserve autoimmune treatment efficacy while lowering infection risk.

Selective GYS1 inhibition lowers pathological tissue glycogen while preserving normal metabolism through isoform-targeted, partial enzyme suppression.

Antisense oligonucleotides suppress MAT1a expression to improve adiposity, insulin sensitivity, triglycerides, and fatty liver.

Specific HPBCD isomers isolated by nanofiltration improve selective cholesterol binding over gross mixtures for targeted therapeutic delivery.

A four-drug hair loss regimen combines DHT inhibition with minoxidil-driven blood flow to improve regrowth while limiting monotherapy side effects.

Bifunctional PROTACs link a VHL ligand to a target binder to recruit E3 ligases and drive selective protein ubiquitination and degradation.

Isoquinoline carboxamides inhibit aberrant Wnt signaling to address cancers, fibrotic disorders, and bone or cartilage diseases.

AAV8-delivered shRNA suppresses SOX4 to improve bile duct development and liver function in Alagille syndrome without transplantation.

Stopping CYP2C9 inhibitors before deuruxolitinib dosing helps limit excess JAK inhibitor exposure and related adverse events.

Biodegradable polymer microneedles combine a flexible backing with homogeneous drug distribution to enable self-application and 24-hour release.

An IV ganaxolone bolus plus continuous infusion maintains therapeutic plasma levels to suppress status epilepticus and prevent relapse.

Chemically modifying only one strand of circular dsDNA lowers immunogenicity while preserving transcription and therapeutic protein expression.

Stimulated immune-cell vesicles combine exosomes, apoptotic bodies, and migrasomes to suppress cancer cells without drug loading.

Optimized cabotegravir particle size and excipients keep high-concentration suspensions resuspendable, stable, and less reactive at injection sites.

A CD79b-targeted immunoconjugate combined with lenalidomide and anti-CD20 therapy extends response duration in relapsing follicular lymphoma.

Hepatic arterial infusion of trifluridine treats liver cancer while limiting liver enzyme rise and avoiding severe toxicity seen with floxuridine.

Selective JAK1/JAK2 inhibitors target JAK/STAT-driven skin inflammation in hidradenitis suppurativa and improve clinical response.

Liposomal brilaroxazine targets psoriatic lesions to reduce skin inflammation and cytokines while limiting systemic side effects.

Targeted CNV detection links schizophrenia-related loci to personalized piracetam therapy, improving efficacy while reducing residual symptoms.

pH-tuned lipid nanoparticles deliver RNA to hepatic stellate cells without ligands, improving stability and helping suppress liver fibrosis.

Specific formula (I) compounds improve STING activation and cytokine signaling to boost interferon-driven antiviral and antitumor immunity.

Small-molecule compounds block the menin-MLL interaction to improve leukemia treatment efficacy and address high relapse in MLL-translocation disease.

A two-phase dienogest and ethinyl estradiol release profile maintains contraceptive efficacy and bleeding control despite missed or delayed doses.

Deoxyguanosine and PNP inhibition restore nucleotide balance in GUK1-related MDDS, raising mtDNA levels and easing multisystem symptoms.

Targeting STAT3 with diarylacetylene compounds suppresses diverse tumor cells at low doses while avoiding the high toxicity of conventional chemotherapy.

Oral dexpramipexole lowers blood and lung eosinophils in moderate to severe eosinophilic asthma, improving lung function and control.

Small-molecule oxadiazole and thiadiazole compounds inhibit PD-1 signaling, offering a simpler oral alternative to biologic immunomodulators.

High-concentration 7-hydroxymitragynine inhalation raises delivered dose and speeds therapeutic onset without adding device complexity.

Rapidly disintegrating oral corticosteroid compositions improve upper GI mucosal contact while limiting systemic absorption and side-effects.

Blocking the PERK-eIF2α adaptive stress pathway exposes PTEN-loss, Myc-activated tumors to lethal proteotoxic stress.

An anti-ticagrelor antibody rapidly restores platelet function during surgery or invasive procedures to reduce bleeding risk.

Structural changes to quinone derivatives improve Leishmania killing while lowering host-cell toxicity and enabling topical or oral treatment.

Prodrug conversion and dosing strategies limit in vivo maribavir isomerization to maintain active drug levels and more consistent antiviral efficacy.

A GC-rich 3′ sequence enables enzymatic tailing of chemically modified mRNA with more uniform long polyA tails for stable expression.

Novel imidazopyridine compounds inhibit ERK5 to suppress tumor growth and address limited treatment response across cancers.

Targeted SMDC pretreatment removes immunosuppressive fibroblasts so CAR-expressing lymphocytes infiltrate tumors more effectively with lower off-target toxicity.

A dual polymer coating on an intracranial balloon catheter enables sustained local drug release in brain tissue while reducing systemic side effects.

A 6-month subcutaneous lenacapavir sodium salt formulation addresses daily PrEP dosing limits while providing long-term HIV-1 and HIV-2 protection.

Urea compounds are engineered to activate orexin receptors, addressing weak receptor modulation in neurological and psychiatric disorders.

Selective benzamide CTPS1 inhibitors curb immune and cancer cell proliferation while avoiding the toxicity seen with non-selective CTPS targeting.

Novel THP-substituted pyrimidinedione compounds stabilize cardiac myosin to improve diastolic function and reduce left ventricular obstruction in HCM.

Cyclohexyl salicylate activates olfactory receptor 2A4/7 to stimulate hair growth and thickening while avoiding the side effects of existing treatments.

Oral acotiamide dosing improves voiding pressure and urine flow while preserving bladder compliance and avoiding cholinergic crisis.